Avizakimab, formerly known as BOS161721, represents a promising clinical approach to treating autoimmune diseases . This biological agent selectively targets interleukin-18 , a key protein implicated in the https://inesgvkc519666.activoblog.com/53001251/avizakimab-a-comprehensive-investigation-into-bos161721-s-capability